Welcome to our dedicated page for Predictmedix news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Predictmedix stock.
Predictmedix AI Inc. (PMEDF) is a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI). The company recently announced a partnership with KGK Science, a renowned name in clinical research, to advance health research and product development. This collaboration aims to introduce transformative changes in healthcare innovation, particularly in clinical trial efficiency and health product development. By leveraging Predictmedix AI's cutting-edge technologies and KGK Science's expertise, the partnership is set to redefine health assessment methodologies and outcomes.
KGK Science, with over 22 years of experience, is known for its expertise in clinical research and regulatory support for nutraceutical, cannabis, and hemp industries. On the other hand, Predictmedix AI's Safe Entry Stations utilize multispectral cameras to predict a variety of health issues, including vital parameters, drug impairment, fatigue, and mental illnesses. Together, these companies are focused on enhancing health research and product development through innovative technologies and creating impactful advancements in healthcare solutions.
Predictmedix Inc. has successfully closed the final tranche of its non-brokered private placement, issuing 1,600,000 units at $0.05 each, raising $80,000. Each unit consists of a common share and half a warrant, with a two-year exercise option at $0.10 per share. The funds will support general operations and technology upgrades. Additionally, the company announced two peer-reviewed publications and significant updates to its AI algorithms, enhancing the accuracy of its Safe Entry Stations, which screen for health issues. A new independent director is being appointed following the resignation of Ajit Kumar.
Predictmedix Inc. has successfully closed the first tranche of a non-brokered private placement, issuing 8,300,000 units at a price of $0.05 per unit, totaling gross proceeds of $415,000. Each unit includes one common share and a half warrant. Proceeds will support operational costs, including technology upgrades. The company recently announced its accuracy rates for health screening solutions and is advancing towards commercialization. Safe Entry technology's peer review process is underway, expected to validate its efficacy within 90 days.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced high accuracy rates for its Fit for Work screening solutions. In a recent study involving 270 participants, the technology achieved a 98.38% accuracy in identifying respiration rate, 98.37% in core body temperature, and 85% in heart rate. Following these results, the company has commenced third-party validation for peer-reviewed publication and is advancing its intellectual property. CEO Dr. Rahul Kushwah emphasized the significance of these findings for enhancing workplace safety globally.
Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) announced a non-binding Letter of Intent (LOI) with KaTron Defence Space for the deployment of 80 Safe Entry Stations in Ankara, Turkey, with annual subscription fees projected at USD$1.4 million (CAD$1.85 million). The order is contingent upon results from an ongoing clinical study, expected to be published in a peer-reviewed journal. This technology aims to enhance workplace safety by screening for impairment and infectious disease symptoms. A formal purchase order is anticipated in the third quarter of 2022.
Predictmedix Inc. has secured a revenue-generating deployment of its Safe Entry Stations at the DeBeers Forevermark Forum 2022, taking place from June 29 - July 1, 2022. This deployment is part of an ongoing partnership with Entertainment Bay, aimed at enhancing health safety protocols at live events. The stations screen for signs of infectious diseases, including COVID-19. CEO Dr. Rahul Kushwah expressed optimism about increased interest from event organizers, indicating potential future deployments.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced its fiscal 2022 results, reporting revenues of $134,820 with a gross profit of $84,820 (63% margin), driven by the scaling of its Safe Entry Station technology. The company achieved a net loss of $1.9 million for the year, compared to a net loss of $1.6 million in 2021. Significant milestones include receiving CE Mark and ISO13485 certification, enabling commercialization in the EU, and initiating a clinical study to enhance its FDA Class II Medical Device application.
Predictmedix Inc. (CSE: PMED)(OTCQB: PMEDF) announced that Interim CEO Dr. Rahul Kushwah will present at the 12th Annual LD Micro Invitational in California on June 7, 2022. The presentation is scheduled for 11:00 a.m. Pacific time at the Four Seasons, followed by one-on-one investor meetings. Predictmedix specializes in rapid health screening solutions powered by AI, offering tools to analyze physiological data and identify health issues, including infectious diseases. For more information, visit www.Predictmedix.com.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) successfully deployed its Safe Entry Station at a major Las Vegas event, demonstrating its rapid health screening technology.
The partnership with Uptown Sports Marketing allowed the Company to showcase its AI-enabled screening solution, evaluating staff and performers for infectious diseases, including COVID-19. Dr. Rahul Kushwah noted the opportunity to engage with numerous hospitality representatives, emphasizing Las Vegas' potential as a deployment market due to its high visitor volume. The Safe Entry Station aims to enhance public health safety.
Predictmedix (CSE:PMED)(OTCQB:PMEDF) shares key milestones in a letter from Interim CEO Dr. Rahul Kushwah, highlighting 2021 as a transformative year. The company's major achievements include the deployment of Safe Entry Stations at high-profile events, receiving CE Mark and ISO13485 certification, and enhancing technology with Edge Computing for quicker screening. Initial commercialization efforts are underway, supported by strategic partnerships. Predictmedix aims to position itself as a leader in health screening solutions and plans to advance R&D, targeting FDA certification for its technology in 2022.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has announced a clinical study set to begin in February 2022 at a North American hospital, aimed at validating its AI-driven Infectious Diseases Detection Solution. The study will utilize the company's Safe Entry Stations to screen staff and incoming patients for infectious diseases, including COVID-19. This step is crucial for FDA Class II medical device certification and commercial launch. Results will be published in a peer-reviewed journal. The study aims to enhance the AI algorithms and data collection, supporting the company's expansion in healthcare.
FAQ
What is the current stock price of Predictmedix (PMEDF)?
What is the market cap of Predictmedix (PMEDF)?
What is Predictmedix AI Inc. known for?
Who is KGK Science and what expertise do they bring to the partnership?
What are the key focus areas of the partnership between Predictmedix AI Inc. and KGK Science?
How do Predictmedix AI's Safe Entry Stations contribute to the partnership?
What are the expected outcomes of the collaboration between Predictmedix AI Inc. and KGK Science?
